Innogenetics Acquires PCR License

An agreement has been announced whereby Roche Diagnostics (Basel, Switzerland) has granted a full, worldwide license for the use of its patented polymerase chain reaction (PCR) technology to Innogentics GmbH (Ghent, Belgium) in the development and commercialization of Innogenetics' molecular diagnostic products.

Under the terms of the agreement, Innogenetics will pay Roche up to U.S.$27.5 million over a four-year period, plus royalties. This broad license will replace the current product-specific licensing agreement, thereby enabling Innogenetics to offer its customers the complete set of PCR reagents and processes to perform PCR-based nucleic acid amplification so they will not have to obtain a separate license from Roche for this purpose. The deal will also allow Innogenetics to fully integrate PCR technology in its next-generation diagnostic platform as well as its complete range of molecular diagnostic tests, thereby ensuring the best test performance.

"We are extremely pleased to have concluded this milestone agreement with Roche Diagnostics,” observed Frank Morich, CEO of Innogenetics. "The availability of PCR for all of our current and future nucleic-acid-based tests will allow us to capitalize on the full potential of our new technology platform, offer our customers the broadest and most up-to-date options for diagnostic testing, and provide Innogenetics with the strategic freedom to further diversify its product offerings and increase diagnostic sales.”





Related Links:
Roche Diagnostics
Innogenetics